Univariable analysis of prognostic predictors in t-ALL
| . | OS . | RFS . | ||||
|---|---|---|---|---|---|---|
| No. of patients . | HR (95% CI) . | P . | No. of patients . | HR (95% CI) . | P . | |
| Age at ALL diagnosis | 116 | 1.007 (0.98-1.02) | .48 | 103 | 1.003 (0.98-1.02) | .80 |
| Sex | .01 | .02 | ||||
| Male | 56 | 1.98 (1.16-3.22) | 56 | 1.80 (1.08-3.01) | ||
| Female | 60 | — | 47 | — | ||
| Prior malignancy | .20 | .42 | ||||
| Hematologic | 44 | 1.41 (0.82-2.41) | 39 | 1.24 (0.73-2.11) | ||
| Solid | 72 | — | 64 | — | ||
| Alkylating agents | .17 | .34 | ||||
| Yes | 71 | 2.67 (0.63-11.18) | 66 | 1.31 (0.74-2.32) | ||
| No | 43 | — | 36 | — | ||
| Topoisomerase II inhibitors | .04 | .56 | ||||
| Yes | 37 | 2.68 (1.01-7.14) | 33 | 1.16 (0.68-1.98) | ||
| No | 78 | — | 70 | — | ||
| Radiotherapy | 8.25 (1.06-64.07) | .04 | .70 | |||
| Yes | 64 | 55 | 1.10 (0.66-1.85) | |||
| No | 51 | 48 | — | |||
| Interdiagnoses interval | 116 | 1.04 (0.98-1.09) | .28 | 103 | 1.03 (0.97-1.08) | .35 |
| Immunophenotype | .33 | .80 | ||||
| B-ALL | 107 | 0.63 (0.25-1.59) | 96 | 0.86 (0.26-2.79) | ||
| T-ALL | 9 | — | 7 | — | ||
| Cytogenetics | .81 | .85 | ||||
| Normal | 27 | 0.96 (0.71-1.29) | 25 | 0.98 (0.72-1.31) | ||
| Abnormal | 79 | — | 70 | — | ||
| MLLr | .26 | .16 | ||||
| Yes | 14 | 2.14 (0.57-8.33) | 14 | 1.62 (0.72-7.14) | ||
| No | 90 | — | 79 | — | ||
| BCR-ABL | .79 | .49 | ||||
| Yes | 26 | 0.92 (0.48-1.74) | 22 | 0.66 (0.21-2.10) | ||
| No | 78 | — | 71 | — | ||
| MDS-like aberrations* | .44 | .75 | ||||
| Yes | 32 | 0.61 (0.17-2.14) | 26 | 0.75 (0.24-2.29) | ||
| No | 72 | — | 67 | — | ||
| WBC count | 110 | 1.001 (0.99-1.01) | .55 | 97 | 1.001 (0.99-1.01) | .59 |
| Percentage of peripheral blasts | 107 | 1.001 (0.99-1.01) | .85 | 94 | 1.001 (0.98-1.02) | .77 |
| Percentage of bone marrow blasts | 100 | 1.008 (0.99-1.02) | .10 | 90 | 1.007 (0.99-1.02) | .16 |
| Extramedullary disease | .08 | .63 | ||||
| Yes | 22 | 6.4 (0.79-51.8) | 19 | 1.17 (0.60-2.27) | ||
| No | 93 | — | 84 | — | ||
| Response to first induction | .001 | .01 | ||||
| CR/Cri | 86 | 0.12 (0.04-0.36) | 86 | 0.21 (0.06-0.76) | ||
| Refractory | 13 | — | 9 | — | ||
| MRD status at response | .37 | .18 | ||||
| Positive | 24 | 1.47 (0.62-3.44) | 20 | 1.75 (0.76-4.04) | ||
| Negative | 23 | — | 23 | — | ||
| Performance of HCT | .01 | .02 | ||||
| Yes | 42 | 0.49 (0.28-0.87) | 42 | 0.25 (0.07-0.86) | ||
| No | 69 | — | 57 | |||
| Conditioning regimen | .46 | .88 | ||||
| Myeloablative | 25 | 0.68 (0.23-1.93) | 25 | 0.92 (0.33-2.53) | ||
| Reduced intensity | 7 | — | 7 | — | ||
| . | OS . | RFS . | ||||
|---|---|---|---|---|---|---|
| No. of patients . | HR (95% CI) . | P . | No. of patients . | HR (95% CI) . | P . | |
| Age at ALL diagnosis | 116 | 1.007 (0.98-1.02) | .48 | 103 | 1.003 (0.98-1.02) | .80 |
| Sex | .01 | .02 | ||||
| Male | 56 | 1.98 (1.16-3.22) | 56 | 1.80 (1.08-3.01) | ||
| Female | 60 | — | 47 | — | ||
| Prior malignancy | .20 | .42 | ||||
| Hematologic | 44 | 1.41 (0.82-2.41) | 39 | 1.24 (0.73-2.11) | ||
| Solid | 72 | — | 64 | — | ||
| Alkylating agents | .17 | .34 | ||||
| Yes | 71 | 2.67 (0.63-11.18) | 66 | 1.31 (0.74-2.32) | ||
| No | 43 | — | 36 | — | ||
| Topoisomerase II inhibitors | .04 | .56 | ||||
| Yes | 37 | 2.68 (1.01-7.14) | 33 | 1.16 (0.68-1.98) | ||
| No | 78 | — | 70 | — | ||
| Radiotherapy | 8.25 (1.06-64.07) | .04 | .70 | |||
| Yes | 64 | 55 | 1.10 (0.66-1.85) | |||
| No | 51 | 48 | — | |||
| Interdiagnoses interval | 116 | 1.04 (0.98-1.09) | .28 | 103 | 1.03 (0.97-1.08) | .35 |
| Immunophenotype | .33 | .80 | ||||
| B-ALL | 107 | 0.63 (0.25-1.59) | 96 | 0.86 (0.26-2.79) | ||
| T-ALL | 9 | — | 7 | — | ||
| Cytogenetics | .81 | .85 | ||||
| Normal | 27 | 0.96 (0.71-1.29) | 25 | 0.98 (0.72-1.31) | ||
| Abnormal | 79 | — | 70 | — | ||
| MLLr | .26 | .16 | ||||
| Yes | 14 | 2.14 (0.57-8.33) | 14 | 1.62 (0.72-7.14) | ||
| No | 90 | — | 79 | — | ||
| BCR-ABL | .79 | .49 | ||||
| Yes | 26 | 0.92 (0.48-1.74) | 22 | 0.66 (0.21-2.10) | ||
| No | 78 | — | 71 | — | ||
| MDS-like aberrations* | .44 | .75 | ||||
| Yes | 32 | 0.61 (0.17-2.14) | 26 | 0.75 (0.24-2.29) | ||
| No | 72 | — | 67 | — | ||
| WBC count | 110 | 1.001 (0.99-1.01) | .55 | 97 | 1.001 (0.99-1.01) | .59 |
| Percentage of peripheral blasts | 107 | 1.001 (0.99-1.01) | .85 | 94 | 1.001 (0.98-1.02) | .77 |
| Percentage of bone marrow blasts | 100 | 1.008 (0.99-1.02) | .10 | 90 | 1.007 (0.99-1.02) | .16 |
| Extramedullary disease | .08 | .63 | ||||
| Yes | 22 | 6.4 (0.79-51.8) | 19 | 1.17 (0.60-2.27) | ||
| No | 93 | — | 84 | — | ||
| Response to first induction | .001 | .01 | ||||
| CR/Cri | 86 | 0.12 (0.04-0.36) | 86 | 0.21 (0.06-0.76) | ||
| Refractory | 13 | — | 9 | — | ||
| MRD status at response | .37 | .18 | ||||
| Positive | 24 | 1.47 (0.62-3.44) | 20 | 1.75 (0.76-4.04) | ||
| Negative | 23 | — | 23 | — | ||
| Performance of HCT | .01 | .02 | ||||
| Yes | 42 | 0.49 (0.28-0.87) | 42 | 0.25 (0.07-0.86) | ||
| No | 69 | — | 57 | |||
| Conditioning regimen | .46 | .88 | ||||
| Myeloablative | 25 | 0.68 (0.23-1.93) | 25 | 0.92 (0.33-2.53) | ||
| Reduced intensity | 7 | — | 7 | — | ||
MDS-like cytogenetic abnormalities included deletions of chromosomes 5, 7, 11, 13, 17, and 20, as well as trisomy 8.